• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Frontiers in Public Health >Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review
【24h】

Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review

机译：用EQ-5D-5L测量的不同疾病患者的健康状生活质量：系统评价

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The EQ-5D-5L is a generic preference-based questionnaire developed by the EuroQol Group to measure health-related quality of life (HRQoL) in 2005. Since its development, it has been increasingly applied in populations with various diseases and has been found to have good reliability and sensitivity. This study aimed to summarize the health utility elicited from EQ-5D-5L for patients with different diseases in cross-sectional studies worldwide. Methods: Web of Science, MEDLINE, EMBASE, and the Cochrane Library were searched from January 1, 2012, to October 31, 2019. Cross-sectional studies reporting utility values measured with the EQ-5D-5L in patients with any specific disease were eligible. The language was limited to English. Reference lists of the retrieved studies were manually searched to identify more studies that met the inclusion criteria. Methodological quality was assessed with the Agency for Health Research and Quality (AHRQ) checklist. In addition, meta-analyses were performed for utility values of any specific disease reported in three or more studies. Results: In total, 9,400 records were identified, and 98 studies met the inclusion criteria. In the included studies, 50 different diseases and 98,085 patients were analyzed. Thirty-five studies involving seven different diseases were included in meta-analyses. The health utility ranged from 0.31 to 0.99 for diabetes mellitus [meta-analysis random-effect model (REM): 0.83, (95% CI = 0.77–0.90); fixed-effect model (FEM): 0.93 (95% CI = 0.93–0.93)]; from 0.62 to 0.90 for neoplasms [REM: 0.75 (95% CI = 0.68–0.82); FEM: 0.80 (95% CI = 0.78–0.81)]; from 0.56 to 0.85 for cardiovascular disease [REM: 0.77 (95% CI = 0.75–0.79); FEM: 0.76 (95% CI = 0.75–0.76)]; from 0.31 to 0.78 for multiple sclerosis [REM: 0.56 (95% CI = 0.47–0.66); FEM: 0.67 (95% CI = 0.66–0.68)]; from 0.68 to 0.79 for chronic obstructive pulmonary disease [REM: 0.75 (95% CI = 0.71–0.80); FEM: 0.76 (95% CI = 0.75–0.77)] from 0.65 to 0.90 for HIV infection [REM: 0.84 (95% CI = 0.80–0.88); FEM: 0.81 (95% CI = 0.80–0.82)]; from 0.37 to 0.89 for chronic kidney disease [REM: 0.70 (95% CI = 0.48–0.92; FEM: 0.76 (95% CI = 0.74–0.78)]. Conclusions: EQ-5D-5L is one of the most widely used preference-based measures of HRQoL in patients with different diseases worldwide. The variation of utility values for the same disease was influenced by the characteristics of patients, the living environment, and the EQ-5D-5L value set. Systematic Review Registration : https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD42020158694.
机译：背景：EQ-5D-5L是由Euroqol集团开发的基于通用的偏好问卷，以衡量2005年的健康相关的生活质量（HRQOL）。自发展以来，它越来越多地应用于各种疾病的人群。被发现具有良好的可靠性和敏感性。本研究旨在总结从EQ-5D-5L引发的卫生效用，对全球横断面研究中的不同疾病的患者。方法：从2012年1月1日至2019年1月1日到2019年1月1日，科学网站，Medline，Embase和Cochrane图书馆进行了搜查。横断面研究报告用任何特定疾病患者的EQ-5D-5L测量的效用值有资格的。该语言仅限于英语。手动搜索检索研究的参考列表以确定符合纳入标准的更多研究。用卫生研究和质量（AHRQ）清单评估方法质量。此外，对三项或更多研究报告的任何特定疾病的效用值进行了荟萃分析。结果：确定了9,400条记录，98项研究达到了纳入标准。在包括的研究中，分析了50种不同的疾病和98,085名患者。涉及七种不同疾病的三十五项研究包括在Meta-Analys中。糖尿病的锻炼效用范围为0.31至0.99 [Meta-Analysis随机效应模型（REM）：0.83，（95％CI = 0.77-0.90）;固定效果模型（FEM）：0.93（95％CI = 0.93-0.93）];为肿瘤0.62至0.90 [REM：0.75（95％CI = 0.68-0.82）; FEM：0.80（95％CI = 0.78-0.81）];为心血管疾病0.56至0.85 [剩余：0.77（95％CI = 0.75-0.79）; FEM：0.76（95％CI = 0.75-0.76）];多发性硬化的0.31〜0.78 [剩余：0.56（95％CI = 0.47-0.66）; FEM：0.67（95％CI = 0.66-0.68）];对于慢性阻塞性肺病的0.68至0.79 [REM：0.75（95％CI = 0.71-0.80）; FEM：0.76（95％CI = 0.75-0.77）]艾滋病毒感染0.65至0.90 [REM：0.84（95％CI = 0.80-0.88）; FEM：0.81（95％CI = 0.80-0.82）];慢性肾病的0.37至0.89 [REM：0.70（95％CI = 0.48-0.92; FEM：0.76（95％CI = 0.74-0.78）]。结论：EQ-5D-5L是最广泛使用的偏好之一 - 基于全球不同疾病患者的HRQOL的措施。同类疾病的效用价值的变化受患者，生活环境和EQ-5D-5L值集的特点。系统评价：HTTPS：/ /www.crd.york.ac.uk/prospero/，标识符CRD42020158694。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号